E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter

About 50–70% of breast cancers are estrogen receptor α (ERα) positive and most of them are sensitive to endocrine therapy including tamoxifen. However, one third of these patients will eventually develop resistance and relapse. We found that the expression of miR-15a and miR-16 were significantly decreased in tamoxifen resistant ER positive breast cancer cell lines. Exogenous expression of miR-15a/16 mimics re-sensitized resistant cells to tamoxifen by inhibiting Cyclin E1 and B cell lymphoma-2 (Bcl-2) to induce cell growth arrest and apoptosis respectively. Further, we identified that a repressive member of E2F family, E2F7, was responsible for the suppression of miR-15a/16 cluster by competing with E2F1 for E2F binding site at the promoter of their host gene DLEU2. Moreover, high expression of E2F7 is correlated with high risk of relapse and poor prognosis in breast cancer patients receiving tamoxifen treatment. Together, our results suggest that overexpression of E2F7 represses miR-15a/16 and then increases Cyclin E1 and Bcl-2 that result in tamoxifen resistance. E2F7 may be a valuable prognostic marker and a therapeutic target of tamoxifen resistance in breast cancer.

[1]  R. Sutherland,et al.  Modulation of the growth-inhibitory effects of progestins and the antiestrogen hydroxyclomiphene on human breast cancer cells by epidermal growth factor and insulin. , 1989, Cancer research.

[2]  Elizabeth Garrett-Mayer,et al.  Cross-study validation and combined analysis of gene expression microarray data. , 2007, Biostatistics.

[3]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  C. Croce,et al.  miR-15a and miR-16-1 in cancer: discovery, function and future perspectives , 2010, Cell Death and Differentiation.

[5]  C. Sweep,et al.  Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer , 2003, Oncogene.

[6]  C. Croce,et al.  miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Hilla Peretz,et al.  Ju n 20 03 Schrödinger ’ s Cat : The rules of engagement , 2003 .

[8]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[10]  D. Ginsberg,et al.  miR-15 and miR-16 Are Direct Transcriptional Targets of E2F1 that Limit E2F-Induced Proliferation by Targeting Cyclin E , 2011, Molecular Cancer Research.

[11]  T. Heinemeyer,et al.  Databases on transcriptional regulation : TRANSFAC , TRRD and COMPEL , 1997 .

[12]  B. Katzenellenbogen,et al.  Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[13]  Tyler E. Miller,et al.  MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1*♦ , 2008, Journal of Biological Chemistry.

[14]  Robert L. Sutherland,et al.  Biological determinants of endocrine resistance in breast cancer , 2009, Nature Reviews Cancer.

[15]  R. Schiff,et al.  Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Hazar-Rethinam,et al.  E2F7 can regulate proliferation, differentiation, and apoptotic responses in human keratinocytes: implications for cutaneous squamous cell carcinoma formation. , 2009, Cancer research.

[17]  Charles P. Lin,et al.  MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. , 2009, Blood.

[18]  N. L. La Thangue,et al.  DNA‐damage response control of E2F7 and E2F8 , 2008, EMBO reports.

[19]  G. Sherbet,et al.  EPIDERMAL-GROWTH-FACTOR RECEPTORS AND OESTROGEN RECEPTORS IN HUMAN BREAST CANCER , 1985, The Lancet.

[20]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[21]  Mauro Biffoni,et al.  The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities , 2008, Nature Medicine.

[22]  C. Osborne,et al.  Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. , 1983, Cancer research.

[23]  S. Lakhani,et al.  Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer , 2014, Oncogenesis.

[24]  Y Pawitan,et al.  Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer , 2013, Oncogene.

[25]  Gianluca Bontempi,et al.  Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen , 2008, BMC Genomics.

[26]  R. Nicholson,et al.  Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. , 2003, Endocrinology.

[27]  F. Yu,et al.  MicroRNA 34c Gene Down-regulation via DNA Methylation Promotes Self-renewal and Epithelial-Mesenchymal Transition in Breast Tumor-initiating Cells* , 2011, The Journal of Biological Chemistry.

[28]  Paul Ellis,et al.  PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer , 2010, Proceedings of the National Academy of Sciences.

[29]  J. Nevins,et al.  Interaction of E2F7 Transcription Factor with E2F1 and C-terminal-binding Protein (CtBP) Provides a Mechanism for E2F7-dependent Transcription Repression* , 2013, The Journal of Biological Chemistry.

[30]  Carme Camps,et al.  microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. , 2011, Cancer research.

[31]  F. Holstege,et al.  E2F7 represses a network of oscillating cell cycle genes to control S-phase progression , 2011, Nucleic acids research.

[32]  M. Hallett,et al.  The prognostic ease and difficulty of invasive breast carcinoma. , 2014, Cell reports.

[33]  Mats Lambe,et al.  Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation , 2012, Clinical Cancer Research.

[34]  Y. Furukawa,et al.  E2F‐6 Suppresses Growth‐Associated Apoptosis of Human Hematopoietic Progenitor Cells by Counteracting Proapoptotic Activity of E2F‐1 , 2007, Stem cells.

[35]  K. Gelmon,et al.  The 2000 EBCTCG overview: a widening gap , 2005, The Lancet.

[36]  S. Sleijfer,et al.  High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer , 2011, Breast Cancer Research and Treatment.

[37]  B. Katzenellenbogen,et al.  Tamoxifen down-regulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance , 2011, Oncogene.

[38]  D. Cittelly,et al.  Oncogenic HER2Δ16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors , 2010, Carcinogenesis.

[39]  Christian Marth,et al.  Clinical Relevance of E2F Family Members in Ovarian Cancer—An Evaluation in a Training Set of 77 Patients , 2007, Clinical Cancer Research.

[40]  Bertrand Baujat,et al.  A graphical method for exploring heterogeneity in meta‐analyses: application to a meta‐analysis of 65 trials , 2002, Statistics in medicine.